Practice Paterns Science Inc., St. Louis, has developed PTE-Registry,™ a national comparative database designed to help pharmaceutical and biotechnology companies identify the drugs that produce more efficient treatment patterns with fewer side effects
Practice Patterns Science Inc., St. Louis, has developed PTE-Registry,⢠a national comparative database designed to help pharmaceutical and biotechnology companies identify the drugs that produce more efficient treatment patterns with fewer side effects.
Educational tool
The database can also be used as a benchmarking tool to help educate health care providers on more effective practice patterns in treating medical conditions.
It can identify reductions in total medical treatment charges, reductions in complications and side effects and, for acute illnesses, reductions in treatment duration.
For health care plans, the database is a resource for comparing one plan's physician network with those of other health plans.
The database uses "diagnostic cluster methodology," a process in which medical and pharmacy claims data are linked to produce a "patient treatment episode." These patient treatment episodes link all charges incurred in treating a patient's medical condition within a specific period of time.
Practice Patterns Science will make a limited summary of the data available to the health care market with the publication of a three-volume set from the database.
The series is called the PPS/GreenBook⢠and includes information about drug treatment for chronic diseases like asthma, diabetes, depression, seizure disorders and peptic ulcer disease.
In the future, Practice Patterns Science plans to expand the database to target Medicare-specific findings using Medicare risk-population data. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.